BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Several other kinase pathways, such as the PI3K/AKT pathway, the JAK STAT pathway, and MEK/ERK kinase pathways are activated by the BCR::ABL oncoprotein in CML, and they play a role in drug resistance, disease progression, and maintenance of the leukemic drive [90,91,92].